Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug development project
|
| gptkbp:acquiredBy |
gptkb:Gilead_Sciences
|
| gptkbp:approvalYear |
2013
|
| gptkbp:clinicalTrialsPhase1Start |
2008
|
| gptkbp:clinicalTrialsPhase2Start |
2010
|
| gptkbp:clinicalTrialsPhase3Start |
2011
|
| gptkbp:constructionStartYear |
2007
|
| gptkbp:developedBy |
gptkb:Pharmasset
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sofosbuvir (development)
|
| gptkbp:indication |
gptkb:Hepatitis_C
|
| gptkbp:mechanismOfAction |
gptkb:NS5B_polymerase_inhibitor
|
| gptkbp:milestone |
First-in-class oral nucleotide analog for HCV
|
| gptkbp:originalCodeName |
gptkb:PSI-7977
|
| gptkbp:relatedTo |
gptkb:Sofosbuvir
|
| gptkbp:bfsParent |
gptkb:Idenix_Pharmaceuticals
|
| gptkbp:bfsLayer |
8
|